期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

HSV-2包膜糖蛋白与疫苗的研究进展 被引量：1

Advances in the research of HSV-2 envelope glycoproteins and vaccines
原文传递
导出
摘要 单纯疱疹病毒（herpes simplex virus，HSV）2型是一种主要引起生殖器疱疹的病原体，它可以在宿主体内终身潜伏并增加人们感染HIV的几率。HSV-2有12个已命名的特异性包膜糖蛋白，它们在病毒的复制和致病中起着至关重要的作用，是细胞免疫和体液免疫的主要靶标，也是预防和治疗HSV-2感染的亚单位疫苗、DNA疫苗或多肽疫苗的候选蛋白。此文综述了HSV-2包膜糖蛋白的特性及以这些糖蛋白为基础的疫苗的研究进展。 Herpes simplex virus type 2 is a major pathogen causing genital herpes. It can create life- long incubation period in the host and increase the risk of HIV infection. Currently, at least 12 viral glycopro- teins are known. They play a vital role in the virus replication cycle and pathogenicity. They are also the targets of cell-mediated and humoral immunity and important candidates for subunit vaccines, DNA vaccines and peptide vaccines to prevent HSV-2 infection. In this review, the characteristics of HSV-2 envelope glycopro- teins and the glycoprotein-based vaccines are discussed.
作者 杜倩 王一飞(综述) 张庶民(审校)
机构地区 暨南大学生物医药研究基地 中国药品生物制品检定所血清室
出处 《国际生物制品学杂志》 CAS 2010年第5期254-259,共6页 International Journal of Biologicals
关键词 HSV-2感染 包膜糖蛋白 亚单位疫苗 单纯疱疹病毒 生殖器疱疹 DNA疫苗 体液免疫 细胞免疫 Herpes virus 2, human Glycoproteins Herpes simplex virus vaccines Immunity, cellular
分类号 R3 [医药卫生—基础医学]
  • 相关文献

参考文献36

  • 1Xu F,Sternberg MR,Kottiri BJ,et al.Trends in herpes simplex virus type1 and type2 seroprevalence in the United States[J].JAMA,2006,296(8):964-973.
  • 2Stanberry LR,Cunningham AL,Mindel A,et al.Prospects for control of herpes simplex virus disease through immunization[J].Clin Infect Dis,2000,30 (3):549-566.
  • 3Herold B,Visalli R,Susmarski N,et al.Glycoprotein C-independent binding of herpes simplex virus to cells requires cell surface heparin sulphate and glycoprotein B[J].J Gen Virol,1994,75(Pt 6):1211-1222.
  • 4Laquerre S,Argnani R,Anderson D,et al.Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C,which differ in their contributions to virus attachment,penetration,and cell-to-cell spread[J].J Virol,1998,72(7):6119-6130.
  • 5Qadri I,Gimeno C,Navarro D,et al.Mutations in conformationdependent domains of herpes simplex virus 1 glycoprotein B affect the antigenic properties,dimerization,and transport of the molecule[J].Virology,1991,180 (1):135-152.
  • 6Chentoufi AA,Binder NR,Berka N,et al.Asymptomatic human CD4+ cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B[J].J Virol,2008,82 (23):11792-11802.
  • 7Neumann J,Eis-Htbinger AM,Koch N.Herpes simplex virus type 1 targets the MHC cbss Ⅱ processing pathway for immune evasion[J].J Immunol,2003,171(6):3075-3083.
  • 8Andersen H,Dempsey D,Chervenak R,et al.Expression of intracellular IFN-gamma in HSV-1-specific CD8+T cells identifies distinct responding subpopulations during the primary response to infection[J].J Immunol,2000,165 (4):2101-2107.
  • 9Manservigi R,Boero A,Argnani R,et al.Immunotherapeutic activity of a combined recombinant gB-gD-gE vaccine against recuurent HSV-2 infections in a guinea pig model[J].Vaccine,2005,23(7):865-872.
  • 10Lee HH,Cha SC,Jang DJ,et al.Immunization with combined HSV-2 glycoproteins B2:D2 gene DNAs:protection against lethal intravaginal challenges in mice[J].Virus Genes,2002,25(2):179-188.

同被引文献11

  • 1Paz-Bailey G, Ramaswamy M, Hawkes SJ, et al. Herpes simplex virus type 2:epidemiology and management options in developing countries [ J ]. Postgrad Med,2008,84. :299.
  • 2Weiss HA, Buye A, Robinson NJ. The epidemiolngy of HSV-2 infection and its association with HIV infection in four urban African populations [ J]. AIDS,2001,15 (4) : 97.
  • 3Wald A, Corey L. How does herpes simplex virus type 2 influence human immunodeficiency virus infection and pathogenesis [ J ]. J Infect Dis,2003,187(10) :1513.
  • 4Akhtar J, Shukla D. Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry [ J ]. FEBS J,2009,276 (24) :7228.
  • 5Manservigi R, Boero A, Afghani R, et al. lmmunotherapeulic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model [ J ]. Vaccine, 2005,23 ( 7 ) : 865.
  • 6Karem KL, Bowen J, Kuklin N, et al. Protective immunity against herpes simplex virus(HSV) typel following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens[ J ]. J Gen Virol, 199,78 ( Pt 2 ) :427.
  • 7G. Mezo,B. Dalmadi,I. Mucsi,et al. Peptide based vaccine design:synthesis and immunological characterization of branched polypeptide conjugates comprising the 276-284 immunodominant epitope of HSV-1 glycoprotein D [ J ] , Journal of Peptide Science, 2002,8(3) :107.
  • 8Bernstein DJ. Effect of route of vaccination with vaccinia virus expressing HSV-2 glycoprotein D on protection from genital HSV-2 infection [ J ]. Vaccine ,2000,18 ( 14 ) : 1351.
  • 9Rux AH, Willis SH, Nicola AV, et al. Functional region IV of glycoprotein D from herpes simplex virus modulates glycoprntein binding to the herpesvirus entry mediator [ J ]. J Virol, 1998,72 (9) :7091.
  • 10Manservigi R, Boero A, Argnani R, et al. hnmunotherapeutic activity of a recombinant combined gB-gD-gE vaeeine against recurrent HSV-2 infections in a guinea pig model [ J ]. Vaccine, 2005,23 ( 7 ) : 865.

引证文献1

国际生物制品学杂志
2010年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部